Circulating white blood cell (WBC) counts (neutrophils, monocytes, lymphocytes, eosinophils, basophils) differ by ethnicity. The genetic factors underlying basal WBC traits in Hispanics/Latinos are unknown. We performed a genome-wide association study of total WBC and differential counts in a large, ethnically diverse US population sample of Hispanics/Latinos †
Introduction
Total white blood cell (WBC) and differential (neutrophil, monocyte, lymphocyte, eosinophil and basophil) counts are indicators of general health and are influenced by inflammatory, immune, allergic and hematologic diseases. During normal hematopoiesis in the bone marrow, WBC production and differentiation are regulated by the coordinated action of hematopoietic growth factor and cytokine signaling, transcriptional regulation and epigenetic modification of lineage-specific genes (1) . Dysregulation of these pathways leads to abnormal differentiation and proliferation of immature progenitor cells that underlies the pathogenesis of leukemia and other clonal hematologic disorders (myeloproliferative neoplasms) (2) .
Circulating WBC counts are heritable, complex, polygenic traits (3) (4) (5) that exhibit a large degree of inter-individual and ethnic variation. Genome-wide association studies (GWAS) have identified approximately 50 genetic loci associated with WBC traits in individuals of European, Asian and African descent (6) (7) (8) (9) (10) (11) (12) . Total WBC and neutrophil counts tend to be lower on average among individuals of African descent compared to other populations (13) . This is partially attributable to the African-derived Duffy antigen receptor for chemokines (DARC) 'null' variant (rs2814778), which is known to confer resistance to Plasmodium falciparum malaria infection (14, 15) .
Hispanics/Latinos in the US are a highly heterogeneous ethnic group with varied proportions of Amerindian, European and African ancestry. Data on WBC trait variability in Hispanic/ Latino populations are fairly limited. Despite the greater proportion of African ancestry, Hispanics/Latino on average have been reported to have higher total WBC and neutrophil counts compared to non-Hispanic whites (16, 17) . Moreover, certain acquired or inherited hematologic conditions such as childhood acute lymphoblastic leukemia (ALL) (18) are more common among Hispanics/Latinos. Whether previously identified or asyet unidentified shared or ethnicity-specific genetic factors contribute to inter-individual WBC trait variability in Hispanics/ Latinos is largely unknown. We therefore performed a GWAS of total WBC count and WBC subtype counts in a large, ethnically diverse US sample ascertained by the Hispanic Community Health Study and Study of Latinos (HCHS/SOL).
Results
Genome-wide association analysis of total WBC and the absolute number of circulating neutrophils, monocytes, lymphocytes, eosinophils and basophils was performed in 11 809 Hispanic-/Latino-Americans from HCHS/SOL. Genomic inflation factors ranged from 1.008 (basophils) to 1.034 (neutrophils), indicating adequate control of population stratification. Quantile-quantile and Manhattan plots are shown in Figure 1 .
Overall, 17 distinct loci, representing 21 combinations of trait-variant associations, were significantly (P < 5 Â 10 À 8 ) or suggestively (P 1 Â 10
) associated with total WBC and/or WBC subtype in the HCHS/SOL Hispanics (Table 1) . Of the 21 trait-variant associations, five were with total WBC, four with neutrophils, one with lymphocytes, five with monocytes, two with eosinophils and four with basophils. Several of these loci (DARC, GATA2, HLA-C, CSF3-PSMD3 and SLCO5A1) were associated with more than one WBC trait.
Generalization of known WBC-associated loci to HCHS/ SOL Hispanics
The genome-wide significant associations in the HCHS/SOL Hispanics/Latinos included several known WBC trait-associated loci (DARC, ITGA4, GATA2, HLA-C; CCDC26-GSDMC; LPAR1 and CSF3-PSMD3) previously identified in GWAS of European, African or Asian descent individuals ( Table 1) . The most strongly associated variant was the African DARC null variant rs2814778 for total WBC and neutrophil count.
We formally tested the generalization of previously reported simple nucleotide polymorphism (SNP) associations with WBC traits to HCHS/SOL Hispanics/Latinos using a directional false discovery rate (FDR)-based procedure described under Methods ( Fig. 2 ; Supplementary Material, Table S1 ). Of 57 WBC unique trait-SNP associations previously reported in European American, African American or Asian descent samples, 38% or 67% showed evidence of generalization to our Hispanic/Latino discovery sample. On a per trait basis, the replication rate was 1 of 4 loci (25%) for basophils, 6 of 13 loci (46%) for eosinophils, 2 of 2 loci (100%) for lymphocytes, 13 of 16 loci (81%) for monocytes, 4 of 5 loci (80%) for neutrophils and 12 of 17 loci (71%) for total WBC. When stratified by ancestry of the discovery sample, the generalization rate was 72% for European Americans, 86% for African Americans and 73% for Asians.
Our sample size in HCHS/SOL is comparable to that of prior GWAS of WBC traits performed in other populations (N ¼ 10 000-15 000) (6) (7) (8) (9) (10) (11) (12) . Nonetheless, our ability to detect generalization of SNPs in some instances may be limited by statistical power. To address this question, we further assessed the directional consistency of SNP effect sizes for those SNPs that failed to generalize by generating a genetic score summing all trait-increasing alleles for each HCHS/SOL participant. For total WBC, monocytes, eosinophils and basophils, there were 5, 3, 7 and 3 SNPs, respectively, that failed to generalize. The P-value for directionally consistent association of the genetic score was 0.34, 0.005, 0.014 and 0.067, respectively, for total WBC, Table S2 ). These results suggest that, at least for monocytes, eosinophils and basophils, low power may contribute to lack of generalization. Failure to generalize might also occur because of differences in allele frequency or linkage disequilibrium (LD) patterns for the index SNP in HCHS/SOL compared to the original population.
Discovery and replication of novel WBC-associated loci
Ten of the genome-wide significant WBC trait-locus associations in HCHS/SOL were not previously reported through GWAS of quantitative WBC traits (Table 1) . These included LINC01132-LOC101927851 rs3009958 for eosinophils; HAAO rs114477531 for total WBC; CRBN rs1669340 for basophils; SLCO5A1 rs2380606 for total WBC and neutrophils; FLT3 rs76428106 for monocytes; JUND rs12973608 for monocytes; CEBPA rs78744187 for basophils and CPXCR1 rs7882966 for neutrophils. In addition to the 10 novel genome-wide significant loci, a SNP on chr14q11 (rs9743723) had a suggestive association with basophils (P ¼ 4 Â 10 À 7 ). The lead SNP rs9743723 is located downstream of CEBPE, which encodes a hematopoietic transcription factor involved in terminal granulocyte differentiation. Other CEBPE variants have been associated with risk of leukemia.
To assess the presence of secondary, independent association signals at any of our genome-wide significant regions, we carried out conditional analyses adjusting for the effect of the lead variant at each genome-significant WBC trait locus in HCHS/SOL. The only locus that showed evidence of independent association signals (P < 5 Â 10 À 8 following conditional analysis) was FLT3, where there was evidence of two independent genome-wide association signals for monocyte count. The lead variant FLT3 rs76428106 C allele (MAF ¼ 1%) was associated with higher monocyte count (P ¼ 8.17 Â 10
). After conditioning on the lead variant, the FLT3 rs7327579 A allele (MAF ¼ 48%) was associated with higher monocyte count (P ¼ 1.24 Â 10 À 8 ) (Fig. 3 ).
Prior to conditional analysis, the P-value for monocyte association for rs7327579 was 3.26 Â 10 À 6 .
On the basis of the HCHS/SOL discovery-stage results and conditional analysis, we selected 11 variants for follow-up/ replication testing in our Hispanic/Latino validation sample BioMe Biobank. These included nine novel genome-wide-significant associations (rs2380606 was associated with both neutrophil count and total WBC), the conditionally independent FLT3 rs7327579 variant for monocyte count, and the suggestive basophil-associated variant CEBPE rs9743723. Nine of ten total variants (except CPXCR1 rs7882966) were available for testing the 11 associations. Of ten associations tested, four were replicated (P < 0.005 with directional consistency) in the Hispanic/Latino validation sample (Table 2) : FLT3 rs7327579 for monocytes, CEBPA rs78744187 for basophils, CEBPE rs9743723 for basophils and CRBN rs1669340 for basophils and a fifth variant FLT3 rs76428106 for monocytes had a suggestive replication (P < 0.009). While this paper was under review, FLT3 rs76428106 and CEBPA rs78744187 were reported to be associated with monocyte-related and basophil-related traits, respectively, in Europeans in a large UK Biobank meta-analysis (19) . In addition, the minor allele of FLT3 rs76428106 was significantly associated with higher total WBC and the minor allele of CEBPA rs78744187 was significantly associated with several red blood cell (RBC) traits [higher RBC count and lower mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH)]. In HCHS/SOL, although none of these additional blood cell trait associations reached genome-wide significance, we confirmed that FLT3 rs76428106 was nominally associated with higher total ln(WBC) (beta ¼ 0.043, SE ¼ 0.20; P ¼ 0.03), while CEBPA rs78744187 was nominally associated with RBC count (beta ¼ 0.042, SE ¼ 0.0085;
Functional annotation and overlap of newly identified FLT3, CEBPA, CEBPE and CRBN-TRNT1 genetic variants with regulatory elements FLT3 rs76428106 is in LD (r 2 ¼ 0.6) with rs79490353, which overlaps a genomic element enriched for H3K4me1 and H3K27ac enhancer histone marks in monocytes (20) and also for H3K4me1, H3K27ac and H3K4me3 in lymphoblastoid cells (GM12878) and primary B cells (21) . In GM12878 lymphoblastoid cells, the genomic element harboring rs79490353 also overlaps a ChIP-Seq (chromatin immunoprecipitation followed by sequencing) peak for the myeloid transcription factor PU.1 (21) . RS7327579 is located within an open chromatin region of a FLT3 intron enriched with the enhancer histone mark H3K4me1 that is found predominantly in monocytes and dendritic cells (20) . Interestingly, the DNase site is hypersensitive in two out of four BLUEPRINT monocyte donors, further supporting a potential role for allele-specific differences in FLT3 gene regulation by this variant. In Europeans and Amerindians, rs7327579 is also in strong LD (r 2 ¼ 0.8) with a common FLT3 missense variant rs1933437 (p.Thr227Met) located in the second Ig-like domain of the extracellular ligand-binding region. This amino acid substitution is predicted to be likely damaging (22) . The CEBPA rs78744187 lead variant is a strong functional candidate due to its location in a K562 myeloid leukemia cell line, CD34þ cell and monocyte DNaseI site and active enhancer region that binds several hematopoietic transcription factors (CEBPb, GATA-2 and TAL-1) in a blood cell-specific manner (20, 22) . Another myeloid-specific regulatory element (enriched for H3K4me1, H3K4me3 and H3K27ac marks in monocytes, macrophages and neutrophils) harbors two additional LD proxy variants, rs958483 and rs73926283.
The lead SNP CEBPE rs9743723 is in LD with several candidate functional SNPs located within promoter or enhancer histone marks and some of these variants have been suggested to influence CEBPE expression (23, 24) . For example, the LD proxy variant rs10143875 is located within a transcribed CEBPE enhancer and is bound in vitro by several transcription factors including PU.1 and Jun in granulocytes and monocytes (20, 22) . It is noteworthy that rs10143875 putatively alters binding motifs for BCL6B and STAT5A; the latter transcription factor has been implicated in basophil and mast cell lineage specification and differentiation (25) . Another proxy SNP, rs2239635, was reported to disrupt binding of the hematopoietic transcriptional repressor Ikaros, which is a negative regulator of basophil production (26) .
The chromosome 3p26 association signal for higher basophil count encompasses several non-coding variants which are ciseQTL for CRBN and TRNT1 in whole blood. The lead CRBN SNP rs1669340 and several proxy variants are located within blood cell epigenomic promoter or enhancer marks (20, 22) .
Discussion
In a GWAS of nearly 12 000 US Hispanics/Latinos, we discovered and replicated several WBC trait loci. These include two independently associated FLT3 signals for monocyte count, two CCAAT/enhancer binding proteins (CEBPE and CEBPA) for basophil count and CRBN for basophil count. The two distinct FLT3 variants rs76428106 and rs7327579 are low-frequency and common, respectively, and have different allele frequencies in different ancestry groups. We also demonstrated the generalizability to Hispanics/Latinos of the majority of WBC trait loci previously identified in GWAS of European, African or Asian ancestry. The new FLT3, CEBPE, CEBPA and CRBN loci suggest that hematopoiesis-related genes that are grossly altered in malignant hematopoiesis can additionally harbor genetic variants with smaller effect magnitudes that influence circulating levels of WBC subtypes in individuals with no known hematological cancers.
FLT3 variants associated with monocyte count
The lead FLT3 variant rs76428106 (associated with higher monocyte count) is intronic and has an allele frequency of $1% in European and Amerindian populations but is monomorphic in African and Asian 1000 Genomes reference populations. After conditioning on the lead FLT3 variant rs76428106, a second FLT3 variant (rs7327579) was independently associated with higher monocyte count. rs7327579 is common (MAF ¼ 48%), but has a large allele frequency differential between African (A allele frequency ¼ 14%) and non-African populations (A allele frequency 54% in Amerindian, 53% in European, 64% in South Asian and 70% in East Asian 1000 Genomes superpopulations).
FLT3 is a receptor tyrosine kinase that regulates early hematopoiesis (27) and is frequently mutated in hematologic malignancies and is an important prognostic factor and therapeutic target for acute myeloid leukemia (AML) (28, 29) . FLT3 is expressed not only on early myeloid progenitors, but also on monocytes and thereby promotes monocyte/macrophage proliferation and differentiation as well as development and activation of monocyte-derived dendritic cells (30, 31) . The two monocyte count-associated FLT3 variants identified in individuals from HCHS/SOL with no know hematological cancers are distinct from the well-characterized activating FLT3 somatic mutations frequently observed in AML. The FLT3 leukemic mutations generally consist of internal tandem duplications and point mutations involving, respectively, the FLT3 juxtamembrane domain and tyrosine kinase domain, and lead to constitutive activation of the FLT3 receptor and dysregulated downstream signaling pathways and ligand-independent myeloid proliferation (29) . The FLT3 monocyte count-associated variants identified in HCHS/SOL likely have subtler effects on later stages of granulocyte/monocyte lineage specification. Given the poorer prognosis of AML among African Americans compared to whites (32) , additional study of FLT3 variants in AML outcomes may be warranted.
CEBPA and basophil count
The basophil association signal on chr19q13.11 is located approximately 30 kb downstream from CEBPA, which encodes C/ EBPa, a transcription factor that plays an essential role in myeloid differentiation and specification of neutrophil, monocyte and basophil lineage fates (33) . The timing of expression of GATA2 and CEBPA are important for myeloid lineage fate, including the production and differentiation of basophils and mast cells (34) . The minor allele of the lead SNP associated with lower basophil count (rs78744187, T allele frequency ¼ 8.4%) is $3-fold more common in Amerindians and Europeans than Africans and Asians. Highly penetrant germline mutations and acquired somatic mutations of CEBPA each contribute to abnormal WBC maturation and the development of AML (25, 26) . Since the basophilassociated candidate functional SNP rs73926283 disrupts a binding site for the ZFX hematopoietic proto-oncogene, further assessment of this basophil count-associated variant may be warranted in the context of leukemia disease progression or treatment resistance (35) .
CEBPE and basophil count
The region on chr14q11.2 associated with basophil count is localized to a 13 kb LD block downstream of CEBPE, encoding CCAAT/enhancer-binding protein e, another CEBP family transcription factor involved in myelopoiesis and terminal granulocyte differentiation (36) (37) (38) . The minor allele of the basophillowering HCHS/SOL index SNP rs9743723 (C, allele frequency ¼ 47%) is also in moderate LD with a set of CEBPE SNPs increased susceptibility to childhood ALL (39, 40) . The higher incidence of ALL and poorer outcomes among Hispanic children have been attributed in part to genetic risk factors associated with Amerindian ancestry (41, 42) . It is interesting to note that the myeloid enhancer containing rs22239630 is bound by Pol II in NB4 cells (an acute promyelocytic leukemia cell line). The same SNP is predicted to disrupt a putative binding site for ZFX, a transcription factor that maintains a stem/progenitor-like immature phenotype and proliferative capacity of leukemia cells in AML, CML and T-ALL (43) . Given the role of CEBPe as a suppressor of myeloid leukemogenesis, the newly identified basophil-associated CEBPE variant may have additional clinical and therapeutic implications for hematologic cancers (44, 45) .
CRBN and basophil count
The chromosome 3p26 association signal for higher basophil count encompasses several non-coding variants of CRBN and TRNT1. Loss-of-function mutations in TRNT1 result in sideroblastic anemia with B-cell immunodeficiency, periodic fevers and developmental delay (46) . CRBN (cereblon), a component of the substrate receptor for an E3 ubiquitin ligase, was recently identified as the molecular target of lenalidomide (LEN), a thalidomide derivative and immunomodulatory drug used to treat hematologic malignancies such as multiple myeloma and 5q-deletion-associated myelodysplastic syndrome (47, 48) . LEN inhibits ubiquitination of endogenous CRBN substrates and also alters ligase substrate specificity to target new proteins for degradation including IKZF1, a transcription factor important for basophil development and a tumor suppressor for leukemia (49) .
Other WBC loci that generalize to Hispanics/Latinos and implications for WBC/immune-related diseases
Other genome-wide significant associations in the HCHS/SOL included several known WBC trait-associated loci previously identified in GWAS of European-, African-or Asian-descent individuals containing genes involved in WBC production, migration or clearance from the circulation (see Table 1 ). Several of these loci may have implications for ethnic or racial disparities in chronic disease health outcomes. For example, the DARCnull rs2814778 genotype has been under selection among Africans as a receptor for Plasmodium vivax malaria and is also a major determinant for ethnic neutropenia, which could have impact on the pathogenesis of diseases such as HIV or minority participant eligibility in cancer clinical trials (due to exclusion on the basis of low blood counts) (13) . Other WBC-associated variants are associated with inflammatory and autoimmune diseases such as GSDMC with inflammatory bowel disease (50), CSF3-PSMD3 with asthma (51), and HLA-C with psoriasis (52), rheumatoid arthritis (53) and Crohn's disease (50) . The GATA2 variant associated with basophil and eosinophil counts in European Americans and Hispanics/Latinos may have implications for the occurrence of hematopoietic disorders (54) as well as allergic diseases such as asthma (55) , which varies in prevalence and morbidity among Hispanic/Latino ethnic subgroups in the United States (56) .
Conclusions
In summary, we provide evidence for considerable shared genetic architecture of WBC traits between Hispanics/Latinos and other ethnic groups. We identified several novel WBC trait loci, including variants of FLT3 associated with monocyte count, and variants of three known regulators of granulocyte and basophil differentiation (CEBPE, CEBPA and CRBN) associated with basophil count. All four of these hematopoiesis-related genes are often grossly altered in hematologic malignancies. Thus, genetic variants with subtler regulatory effects on the same genes may influence circulating levels of WBC subtypes during normal hematopoiesis. Further studies are warranted to assess whether any of these basophil-associated genetic variants are associated with disease susceptibility or outcomes related to leukemia and myeloproliferative neoplasms.
Materials and Methods

HCHS/SOL population
The HCHS/SOL is a community-based cohort study of 16 415 self-identified Hispanic/Latino persons aged 18-74 years selected from households in predefined census-block groups from four US field centers (Chicago, Miami, the Bronx and San Diego). Participants self-identified as having a Hispanic/Latino background; the largest groups were Central American (n ¼ 1 730), Cuban (n ¼ 2 348), Dominican (n ¼ 1 460), Mexican (n ¼ 6 471), Puerto Rican (n ¼ 2 728) and South American (n ¼ 1 068). The sample design and cohort selection have been previously described (57) . HCHS/SOL participants were recruited between 2008 and 2011 and underwent a baseline clinical examination (58) including biological, behavioral and sociodemographic assessments. The study was approved by the institutional review boards at each field center, where all subjects gave written informed consent.
Measurement of WBC and exclusion criteria in HCHS/SOL
Total WBC and differential counts were measured in EDTA whole blood obtained at the baseline examination using a Sysmex XE-2100 instrument (Sysmex America) at the University of Minnesota according to national and international standards and procedures. Individuals pregnant at the time of blood draw; those with >5% circulating blasts or immature cells, end-stage renal disease or any hematologic malignancy; and those undergoing chemotherapy for solid tumors were excluded from our analyses.
Genotyping, imputation and quality control in HCHS/SOL
Consenting HCHS/SOL subjects were genotyped at Illumina on the HCHS/SOL custom 15041502 B3 array. The custom array comprised the Illumina Omni 2.5M array (HumanOmni2.5-8v.1-1) plus $150 000 custom SNPs including ancestryinformative markers, known GWAS hits and drug absorption, distribution, metabolism and excretion (ADME) markers, and SNPs selected from the CLM (Colombian in Medellin, Colombia), MXL (Mexican Ancestry in Los Angeles, California) and PUR (Puerto Rican in Puerto Rico) samples in the 1000 Genomes phase 1 data to capture a greater amount of Amerindian genetic variation.
We applied standardized quality-assurance and qualitycontrol (QA/QC) methods (59) to generate recommended SNPand sample-level quality filters. Samples were checked for sex discrepancies, gross chromosomal anomalies, relatedness and population structure, missing call rates, batch effects and duplicate-sample discordance. After excluding participants who were ineligible or missing phenotype or genotype data, 11 809 study participants were available for analysis. SNPs were checked for Hardy-Weinberg equilibrium, minor allele frequency (MAF), duplicate-probe discordance, Mendelian errors and missing call rate. A total of 2 232 944 SNPs passed filters for both quality and informativeness (polymorphic and unduplicated) and were carried forward for imputation and downstream association analyses.
Genome-wide imputation in HCHS/SOL was carried out using the full, cosmopolitan 1000 Genomes Project phase 1 reference panel (n ¼ 1 092) (60), as previously described (61) . Briefly, genotypes were first pre-phased with SHAPEIT2 (v.2.r644) and then imputed with IMPUTE2 (v.2.3.0) (62, 63) . Overall imputation quality was assessed by calculating 'oevar' (the ratio of the observed variance of imputed dosages to the expected binomial variance) using the MaCH imputation software (64) and by examination of the distribution of imputation quality metrics from the IMPUTE2 internal masking experiments. We performed downstream association analyses on observed variants passing quality filters and all imputed variants (a total of 27 887 661 variants). Results were then filtered on the basis of imputation quality (oevar > 0.3) and allele frequency (MAF > 1%).
Linear mixed-effect model for association testing in HCHS/SOL
We analyzed WBC phenotypes by using linear mixed-effect models (LMMs) to account for the correlations due to genetic relatedness (kinship), shared household and block group between individuals. All analyses were adjusted for sex, age, five principal components (PCs), recruitment center, smoking status, log of sampling weights (to prevent potential selection bias due to the sampling scheme) and genetic-analysis group (a six-level categorical variable derived from genetic data and selfidentified background) (61) . To approximate normal distribution of the model's residuals, the outcomes were either logtransformed (WBC, lymphocytes) or log transformed after addition of the constant 1 (neutrophils, monocytes, eosinophils, basophils). For basophils, we also performed a sensitivity analyses due to the large numbers of zero values due to rounding. In the sensitivity analysis, we dichotomized basophil count to 0 vs. non-zero, and we applied a score test based on a logistic mixed model, with the same fixed and random effects as before (65) .
Replication of discovery loci in independent Hispanic/ Latino samples
To replicate association findings in Hispanic/Latino samples, we used 1000 Genomes imputed GWAS data available in three additional Hispanics/Latinos samples, including up to 3 454 from the WHI SHARe project (66); 782 from the MESA cohort (67,68) and 2 854 from Mount Sinai BioMe Biobank (69) . WHI-SHARe and MESA participants were genotyped with the Affymetrix 6.0 chip, and imputation was performed with MaCH (64) . BioMe participants were genotyped with the Illumina HumanOmniExpressExome-8 v.1.0 chip, and imputation was performed with IMPUTE2 (62, 63) in 1000 Genomes phase 1 data (March 2012 v.3). Association testing for typed or imputed SNPs was performed by linear regression of log-transformed WBC count adjusted for age, sex and PCs. Meta-analysis of results from the three replication cohorts for total WBC and WBC subtypes was performed with the inverse-variance-weighted method implemented in METAL (70) . To declare significance for replicated WBC loci, we required that (a) the directionality of effect was similar across the discovery and replication phases and (b) the replication P-value met the Bonferroni corrected criteria for multiple testing (P-value <0.05/10 ¼ 0.005).
Generalization in HCHS/SOL
We performed generalization analysis for WBC-associated SNPs previously reported in GWASs of other populations, including those of European, African and Japanese ancestry (2, (6) (7) (8) (9) (10) (11) . In testing for generalization we controlled the directional FDR of the generalization null hypotheses at a threshold of 0.05 (71, in press ). The generalization null hypothesis states that the effect does not exist in either the discovery study nor in HCHS/SOL and is rejected if there is enough evidence that a SNP affects the outcome, with the same direction of effect, in both the discovery study and HCHS/SOL. A SNP was generalized if its r value <0.05.
Functional annotation of discovery loci
We interrogated the WBC-associated loci to determine whether the identified non-coding SNPs and indels and correlated proxy variants (r 2 ! 0.5, calculated in the HCHS/SOL discovery population) were positioned within predicted regulatory regions, namely enhancers and promoters and the nearest biologically plausible gene or genes. These regulatory regions were identified on the basis of the enrichment of various histonemodification and ChIP-seq signals in WBCs (granulocytes, lymphocytes, monocytes, dendritic cells) and bone marrow precursor cells from the Blueprint project (20) . A genomic element enriched with the histone H3K4me1 signal was categorized as an enhancer, whereas a genomic element enriched with the histone H3K4me3 signal was categorized as a promoter. SNPs or indels belonging to either promoter or enhancer categories that overlap a DNase I hypersensitive site (a general biochemical feature of regulatory regions) in blood or bone marrow-derived cells were prioritized as putatively functional variants. We also reported whether a given SNP overlaps with any transcription factor ChIP-seq peaks (72) . Moreover, because related cell types can share similar regulatory regions, we additionally reported supplementary annotation by using data on other myeloid lineage cells and GM12878 lymphoblastoid cells (72) . To identify the motifs disrupted by alleles, we utilized HaploReg (v4) (21) and the JASPAR motif database (73) .
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